Related Experiment Video
Updated: Apr 25, 2026
10:28
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
Published on: June 26, 2020
9.4K
Treating hepatitis C in the elderly: the future is near?
Fabio Conti1, Giovanni Vitale, Pietro Andreone
1University of Bologna, Department of Medical and Surgical Sciences , Via Massarenti, 9, 40138 Bologna , Italy.
Expert Opinion on Pharmacotherapy
|August 27, 2014
Summary
Hepatitis C treatment in older adults using older therapies shows lower response rates and higher discontinuation. Newer interferon-free options may improve outcomes for this growing patient population.
Area of Science:
- Hepatology
- Geriatric Medicine
- Virology
Background:
- The aging global population means hepatitis C virus (HCV) is increasingly prevalent in older individuals.
- Older adults (over 70) are often excluded from clinical trials, complicating treatment decisions.
- Hepatitis C is shifting towards becoming a disease predominantly affecting the elderly.
Purpose of the Study:
- To analyze treatment outcomes in elderly patients with hepatitis C.
- To evaluate response rates and inform therapeutic decision-making for geriatric populations.
- To assess the efficacy and safety of different hepatitis C treatment regimens in older adults.
Main Methods:
- Review of treatment outcomes in geriatric patients with HCV.
- Analysis of response rates and discontinuation rates for various antiviral therapies.
- Examination of side effect profiles, particularly in elderly patients with comorbidities.
Main Results:
- Dual therapy (pegylated IFN plus ribavirin) demonstrated lower sustained virologic response and higher discontinuation rates in geriatric HCV patients.
- First-generation protease inhibitors were associated with significant side effects in the elderly, especially those with comorbidities.
- Elderly patients experienced poorer outcomes with traditional dual therapies.
Conclusions:
- Traditional dual therapies are less effective and more challenging for elderly hepatitis C patients.
- Interferon-sparing regimens represent a promising advancement, potentially expanding access to effective antiviral treatment for older adults.
- Newer treatment strategies are needed to improve hepatitis C management in the growing geriatric population.
More Related Videos
Related Concept Videos
01:25Hepatitis
78
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
78
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
378
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
378
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
379
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
379
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
393
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
393
01:28Viral Hepatitis I: Introduction
18
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
18
01:15Drug Dosing: Geriatric Patients
392
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
392